Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015 (2015), Article ID 590851, 8 pages
http://dx.doi.org/10.1155/2015/590851
Clinical Study

Inflammatory Biomarkers in Refractory Congestive Heart Failure Patients Treated with Peritoneal Dialysis

1Nephrology and Hypertension Institute, Sheba Medical Center and Sackler Faculty of Medicine, 5265601 Tel-Hashomer, Israel
2Heart Failure Service and Heart Institute, Sheba Medical Center and Sackler Faculty of Medicine, 5265601 Tel-Hashomer, Israel

Received 4 March 2015; Revised 4 May 2015; Accepted 5 May 2015

Academic Editor: Francesco Nicolini

Copyright © 2015 Margarita Kunin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Proinflammatory cytokines play a pathogenic role in congestive heart failure. In this study, the effect of peritoneal dialysis treatment on inflammatory cytokines levels in refractory congestive heart failure patients was investigated. During the treatment, the patients reached a well-tolerated edema-free state and demonstrated significant improvement in NYHA functional class. Brain natriuretic peptide decreased significantly after 3 months of treatment and remained stable at 6 months. C-reactive protein, a plasma marker of inflammation, decreased significantly following the treatment. Circulating inflammatory cytokines TNF-α and IL-6 decreased significantly after 3 months of peritoneal dialysis treatment and remained low at 6 months. The reduction in circulating inflammatory cytokines levels may be partly responsible for the efficacy of peritoneal dialysis for refractory congestive heart failure.